The 3 questions every investor in Sirius Minerals plc must ask

Do you have the patience of a saint? Then Sirius Minerals plc (LON: SXX) is the stock for you, says Harvey Jones.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It has been a dull start to the year for British potash prospect Sirius Minerals (LSE: SXX), confounding its reputation as one of the most exciting stocks around. After a spike last autumn its share price has gone nowhere. Today it trades at just 19p, well below its year-high of 51.75p.

Many investors will be frustrated but they shouldn’t be surprised. I’m not. I wrote in November that this is a long-term investment and news flow would be slow. The company is still piecing together its ambitious plans to build one of the world’s largest polyhalite mines under the North Yorks Moors National Park and bore a 23-mile tunnel to a purpose-built export berth in Wilton, Teesside.

I presciently wrote that: “Investors may hear little for months, during which time the share price is likely to drift downwards, as investors get bored, lose interest or spot more enticing prospects.” Which is exactly what is happening. Does this sound like the right stock for you? Find out by answering these three questions.

How long are you investing for?

Sirius Minerals has drawn up a string of long-term contracts to supply multi-nutrient fertiliser, notably to China, yet it won’t serve up a plateful of potash until 2022 at the earliest. That means no revenues for at least five years, while racking up hefty debts to build the infrastructure it requires. It has already taken on around £3.7bn and this could rise if costs overrun.

So you could be twiddling your fingers for some time, or nervously drumming them, as you hang on to see whether the project will succeed. There won’t be any dividends while you wait either. I wrote in December that you will need the patience of a saint. Are you that saint?

Are you aware of the risk of shareholder dilution?

Personally, I’m happy to give Sirius time, but one thing would make me very unhappy. If the company needs to raise further funds, which I reckon is likely given the project’s engineering complexity, shareholders could suffer further dilution, even though the company is trying to fund as much of the capital requirement as possible by debt.

Dilution will hurt, although that should be more than offset by the long-term value of the project. Once the potash hits Teesside, the company will look a very different proposition, and its valuation should rocket. But your eyes could water along the way.

What is the opportunity cost?

There is no question that Sirius Minerals is a massive prospect, as it plans to initially produce 10m tonnes of polyhalite fertiliser a year, with the capacity to double output. Management estimates the project has a net present value of $15.2bn, with prospective annual earnings of between $1bn and $3bn, yet its market capitalisation is a paltry £791m.

However, you also have to factor-in the opportunity cost of investing in Sirius rather than something where the potential rewards will start flowing from day one.

Harvey Jones has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

Here’s 1 passive income stock yielding 10%+ today!

Zaven Boyrazian's on the hunt for high-yield income stocks that most investors are ignoring and has spotted one 10%-plus-yielding potential…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 7.1% forecast yield and 51% below ‘fair value’! 1 of my top FTSE stocks to buy right now

This FTSE giant is rarely seen as one of the obvious stocks to buy for dividend and price gains, but…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

£20,000 invested in HSBC shares 2 years ago is now worth…

HSBC shares have doubled in two years — but with key profitability targets raised, the latest numbers hint the real…

Read more »

A multiracial family of four, a mother, father and their two little boys on a staycation in the city of Newcastle on a sunny winters day
Investing Articles

No savings in your 40s? Start drip feeding £500 a month into UK shares in an ISA to aim for financial freedom

Got nothing in the bank and worried about retirement? Zaven Boyrazian explains how investing in UK shares today could help…

Read more »

Smartly dressed middle-aged black gentleman working at his desk
Investing Articles

Consider these FTSE 100 bargain shares in a Stocks and Shares ISA!

These FTSE 100 shares are trading on rock-bottom P/E and PEG ratios. Royston Wild explains what makes them stunning value…

Read more »

Artillery rocket system aimed to the sky and soldiers at sunset.
Investing Articles

This storming penny stock has already climbed nearly 50% in 2026!

Here's a penny stock that's been taking the defence sector by storm, and its future order book is building up…

Read more »

UK supporters with flag
Investing Articles

Should I buy this ridiculously cheap FTSE 250 stock today?

This FTSE 250 stock has one of the lowest P/E ratios in the index despite profits and margins surging higher.…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Investing Articles

57% under ‘fair value’ and 74% forecast earnings growth! 1 FTSE high-tech med stock I just can’t pass up

This FTSE high‑tech innovator’s earnings look set to soar -- yet it’s still priced as a risky biotech. The disconnect…

Read more »